Subsequently, Tsou et al., introducing a lipophilic substituent at the para position of the 4-arylamino ring, isolated the molecule HKI-272, more active than pelitinib, and approved in 2017 with the name neratinib (Figure 18) for the extended adjuvant therapy against early-stage HER2/ErbB2-amplified/overexpressed breast cancer [3,4,109,111,112]. The gene discussed is ERBB2; the disease is breast cancer.